A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus
Public ClinicalTrials.gov record NCT02106364. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naïve Patients With Type 2 Diabetes Mellitus: An Open-Label, Randomized, 52-week Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to compare the efficacy and safety of a new basal insulin, insulin peglispro, to insulin glargine in participants with type 2 diabetes mellitus (T2DM). Both drugs will be given by an injection under the skin. Participants may continue to take oral antihyperglycemic medication (OAM) during the study, as prescribed by their personal physician. The study is expected to last about 12 months for each participant.
Study identification
- NCT ID
- NCT02106364
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 20 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2015 (Type not available)
- Primary completion
- Nov 2015 (Estimated)
- Completion
- Jun 2016 (Estimated)
- Last update posted
- Mar 28, 2016
2015 – 2016
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rheumatology Associates PC | Birmingham | Alabama | 35205 | — |
| Florida Medical Clinic PA | Zephyrhills | Florida | 33542-7505 | — |
| Diagnostic Rheumatology and Research | Indianapolis | Indiana | 46227 | — |
| Heartland Research Associates | Wichita | Kansas | 67207 | — |
| Washington University Medical Center | St Louis | Missouri | 63110 | — |
| Albuquerque Rehabilitation & Rheumatology, PC | Albuquerque | New Mexico | 87102 | — |
| PMG Research of Hickory, LLC | Hickory | North Carolina | 28602 | — |
| Carolina Arthritis Associates | Wilmington | North Carolina | 28401 | — |
| STAT Research | Dayton | Ohio | 45417 | — |
| Apex Clinical Research | Kennewick | Washington | 99336 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02106364, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 28, 2016 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02106364 live on ClinicalTrials.gov.